

IRG1 controls host responses to restrict *Mycobacterium tuberculosis* infection

Arnaud Machelart¹, Imène Belhaouane¹, Nathalie Deboosere¹, Isabelle Poncin², Jean-Paul Saint-André³, Anne-Marie Pauwels^{4,5}, Ok-Ryul Song¹, Samuel Jouny¹, Carine Rouanet¹, Anaïs Poncet¹, Sabrina Marion¹, William Laine⁶, Jérôme Kluza⁶, Eric Muraille^{7,8}, Rudi Beyaert^{4,5}, Laleh Majlessi⁹, Stéphane Canaan², Priscille Brodin^{1,*}, Eik Hoffmann^{1,*}

¹ Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France

² Aix-Marseille Univ., CNRS, UMR 7255 - LISM, IMM - FR3479, Marseille, France

³ University Hospital Center of Angers, Angers, France

⁴ Unit of Molecular Signal Transduction in Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium

⁵ Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium

⁶ Institut pour la Recherche sur le cancer de Lille (IRCL), Canther, INSERM UMR 9020 – UMR-S 1277, Lille, France

⁷ Unité de Recherche en Biologie des Microorganismes (URBM), NARILIS, University of Namur, Namur, Belgium

⁸ Université Libre de Bruxelles, Laboratoire de Parasitologie, and ULB Center for Research in Immunology (U-CRI), Gosselies, Belgium

⁹ Institut Pasteur – TheraVectys Joint Lab, Virology Department, Paris, France

*To whom correspondence should be addressed:

Eik Hoffmann; E-mail: eik.hoffmann@ibl.cnrs.fr; Tel.: +33 320 871 189

Priscille Brodin; E-mail: priscille.brodin@inserm.fr; Tel.: +33 320 871 184

Short title: Immunometabolic host response to tuberculosis

Keywords: host-pathogen interactions, metabolic reprogramming, tuberculosis, lipid droplet, macrophage, dendritic cell

1 **Abstract**

2 *Mycobacterium tuberculosis* (*Mtb*), the pathogen causing human tuberculosis, has evolved multiple
3 strategies to successfully prevent clearance by immune cells and to establish dissemination and long-term
4 survival in the host. The modulation of host immunity to maximize pathogen elimination while minimizing
5 inflammation-mediated tissue damage may provide another tool to fight drug-resistant *Mtb* strains.
6 Metabolic reprogramming of phagocytes can dramatically influence the intracellular colonization by *Mtb* and
7 the key players involved in this process remain a matter of debate. Here, we demonstrate that aconitate
8 decarboxylase 1 (*Acod1*; also known as immune-responsive gene 1, IRG1), which converts cis-aconitate
9 into the metabolite itaconate, is a major player in controlling the acute phase of *Mtb* infection. Exposure of
10 IRG1-deficient mice to a virulent *Mtb* strain (H37Rv) was lethal, while *M. bovis* BCG and the H37Ra
11 attenuated *Mtb* strain induced neither lethality nor severe lung immunopathology. Lungs of IRG1-deficient
12 mice infected by *Mtb* H37Rv displayed large areas of necrotizing granulomatous inflammation and
13 neutrophil infiltration, accompanied by reduced levels of B and T lymphocytes and increased levels of
14 alveolar and interstitial macrophage populations, compared to their wild type counterparts. Next, we show
15 that IRG1, beyond its recruitment to *Mtb*-containing vacuoles, restricts *Mtb* replication and lipid droplets
16 accumulation in phagocytes, hallmarks of a tight interplay between the bacillus and the host. Altogether,
17 IRG1 confines the host response to create a favourable phagocytic environment for *Mtb* controlled
18 intracellular replication.

19 Introduction

20 Protective immunity of host cells during their infection by bacterial pathogens includes a broad variety of
21 pathways and spatially regulated molecular players. Although the interplay between mechanisms of
22 antimicrobial resistance and adapted tolerance of inflammatory responses is able to control infection, e.g.
23 in the lung, several pathogens have evolved strategies to resist host defense and to persist for long time
24 periods. *Mycobacterium tuberculosis* (*Mtb*), responsible for tuberculosis (TB) in humans, is transmitted by
25 aerosol droplets followed by engulfment by alveolar macrophages and dendritic cells (DCs) in the lung. *Mtb*
26 is able to evade different innate antimicrobial mechanisms of host cells and replicates intracellularly [1]. In
27 addition, host adaptive immune responses are activated and slow down mycobacterial growth, but *Mtb*
28 infection can also lead to chronic forms of TB. Therefore, TB remains a leading cause of death worldwide,
29 responsible for an estimated 1.5 million deaths each year, together with a dramatic increase in the
30 emergence of multidrug- and extensively drug-resistant *Mtb* strains [2]. While any organ in the body can be
31 affected by *Mtb* infection, new infectious cycles are induced by transmission of pulmonary forms of the
32 disease [2]. The live attenuated *Mycobacterium bovis* strain Bacillus Calmette-Guérin (BCG) is the only
33 available vaccine against TB, but is not sufficiently successful in preventing active TB in adults. BCG
34 generates prolonged antigen-responsive CD4 and CD8 T cell responses and remains the gold standard in
35 animal vaccine studies [3].

36 Host-directed therapies (HDTs) against bacterial infections are in development that support
37 elimination of mycobacteria by the host while reducing tissue damage induced by the infection [4].
38 Advances in the understanding of key players involved in immunometabolism shed light on the intimate link
39 between metabolic states of immune cells and their specific functions during infection and inflammation [5,
40 6] and are increasingly applied for the development of HDTs against different infectious diseases, including
41 TB [7]. The *Mtb*-infected host cell microenvironment is characterized by dysregulated immunoregulation
42 pathways, for example, Th1/Th17 versus Th2 balance, regulatory T and suppressive myeloid cell
43 populations and a shift from M1-like to M2-like polarized macrophages [1]. Recent studies have shown that
44 changes in specific host metabolites can be mapped to cellular effector mechanisms and drive different
45 inflammatory phenotypes of immune cells [8]. Itaconate, a host metabolite that is produced by different
46 immune cell populations upon pro-inflammatory stimuli, such as LPS and type I and II interferons [9, 10],

47 was also found in the lungs of *Mtb*-infected mice [11] and received increasing attention in recent years [12,
48 13]. Itaconate is generated from cis-aconitate in the tricarboxylic acid (TCA) cycle by the catalytic enzyme
49 immune-responsive gene 1 (IRG1), also known as aconitate decarboxylase 1 (ACOD1) [14]. It has
50 previously been shown that itaconate has antimicrobial activity by inhibiting isocitrate lyase [15], an enzyme
51 of the glyoxylate shunt, which is present in most prokaryotes but absent in mammals. On the host side,
52 itaconate was shown to affect major inflammatory pathways in immune cells by blocking succinate
53 dehydrogenase [16], by controlling IL-1 β expression and NLRP3 inflammasome activation [17, 18, 19], and
54 by regulating HIF-1 α activity, production of antimicrobial ROS and NO by Nrf2 activation [17, 20, 21]. In
55 turn, itaconate was also recently shown to suppress M2 macrophage polarization [22]. Itaconate activities
56 are able to influence host-pathogen interactions, as it was shown during infections by *Legionella*
57 *pneumophila* [23, 24], *Pseudomonas aeruginosa* [25], Zika virus [26], *Francisella tularensis* [27],
58 *Salmonella enterica* [28], *Staphylococcus aureus* [29] and *Brucella melitensis* or *B. abortus* [30, 31].
59 Concerning TB, Nair et al. showed that IRG1-deficient mice are highly susceptible to *Mtb* infection, while
60 no aberrant phenotypes were found during influenza A virus or *Listeria monocytogenes* infection [32]. Their
61 findings suggest that IRG1 expression in myeloid cells shape immunometabolic host responses by
62 regulating neutrophil-dependent inflammation during *Mtb* infection of the lung. However, the underlying
63 intracellular activities of *Mtb*-infected immune cells and their contribution to the observed phenotype
64 remained unknown.

65 Similar to the previous report using aerosol infection [32], we show here that intranasal inoculation
66 of IRG1-deficient mice by *Mtb* H37Rv induced severe lung immunopathology and mortality of infected mice.
67 Exacerbated inflammation and high mycobacterial burden in the lungs of *Mtb*-infected, IRG1-deficient mice
68 were accompanied by large areas of necrotizing granuloma formation, neutrophil infiltration and a
69 pronounced reduction in the number of B and T lymphocytes. Interestingly, exposure of IRG1-deficient mice
70 to the attenuated *Mtb* strain H37Ra or the vaccinal *M. bovis* BCG strain via the intranasal route induced
71 neither lethality nor severe lung immunopathology demonstrating that the phenotype observed in *Mtb*-
72 infected mice is linked to pathogenic virulence. Moreover, we show that IRG1 is induced upon *Mtb* infection
73 and is directly recruited to *Mtb*-containing phagosomes. IRG1-deficient phagocytes showed elevated *Mtb*
74 infection rate and increased *Mtb* growth in comparison to WT cells resulting in increased mycobacterial

75 numbers *in vitro* after 4 days post-infection. These observations are accompanied by findings that
76 demonstrate that IRG1-deficient macrophages and dendritic cells (DCs) have increased levels of lipid
77 droplets (LDs), which are reservoirs of host nutrients for *Mtb*. Therefore, our findings demonstrate that IRG1
78 is a major player in controlling the acute phase of *Mtb* infection by regulating inflammatory responses and
79 availability of host nutrients.

80 **Results**

81 We explored the physiological relevance of IRG1 deficiency during *Mtb* infection *in vivo* using an infection
82 model established in C57Bl/6 mice. A previous study demonstrated that, compared to WT mice, IRG1-
83 deficient mice (IRG1^{-/-}) were more susceptible to aerosol infection with the *Mtb* Erdman strain [32]. Here,
84 we comparatively evaluated the impact of an intranasal inoculation of WT and IRG1^{-/-} mice by a high dose
85 (10⁵ CFU per mouse) of the virulent *Mtb* H37Rv strain, the attenuated strain *Mtb* H37Ra and the vaccinal
86 mycobacterial strain *M. bovis* BCG 1173P2 (**Figure 1A**). We monitored pathologic parameters, changes in
87 body weight and survival as well as mycobacterial burden during the course of infection for 84 days post-
88 infection (dpi). During the first two weeks post-infection, no apparent differences in body weight of WT and
89 IRG1^{-/-} mice, infected with the different mycobacterial strains, were apparent (**Figure 1B**). From 14 dpi
90 onwards, IRG1^{-/-} mice exposed to *Mtb* H37Rv started to rapidly lose weight (approximately one gram daily),
91 while WT mice exposed to virulent and attenuated strains, as well as IRG1^{-/-} mice exposed to *Mtb* H37Ra
92 and BCG were not affected (**Figure 1B**). The rapid loss in body weight of *Mtb* H37Rv-infected IRG1^{-/-} mice
93 was accompanied by other clinical symptoms, such as shortness of breath and lethargy, and the mice
94 reached moribund conditions and died between 3 to 4 weeks post-infection (**Figure 1C**), similar to IRG1^{-/-}
95 mice infected by *Mtb* Erdman [32]. In contrast, all infected WT mice as well as IRG1^{-/-} mice exposed to *Mtb*
96 H37Ra and BCG did not display loss in body weight nor morbidity and mortality, which we followed up until
97 84 dpi (**Figure 1B-C**). These observations confirm a substantial susceptibility of mice to virulent *Mtb*
98 infection in the absence of functional IRG1. Therefore, we next focussed on immunopathology and
99 mycobacterial burden of infected organs of the differently infected WT and IRG1^{-/-} mice.

100 At 21 dpi, the lungs of *Mtb* H37Rv-infected IRG1^{-/-} mice were enlarged and displayed macroscopic
101 pathological features with areas of necrotizing lesions (**Figure 1D**), while these observations were absent
102 in lungs of mice infected with *Mtb* H37Ra or BCG (**Figure S1**). Histological examination of the lungs using
103 hematoxylin phloxine saffron staining showed massive granulomatous inflammation in *Mtb* H37Rv-exposed
104 IRG1^{-/-} mice compared to their WT counterparts (**Figure 1E**). Ziehl-Neelsen staining of mycobacteria
105 applied to the histological lung sections detected substantial amounts of invading *Mtb* H37Rv in the lung
106 parenchyma of IRG1^{-/-} mice (**Figure 1F, inset 2**), while lungs of WT mice contained much lower numbers
107 of bacteria (**Figure 1F, inset 1**). Determination of pulmonary mycobacterial loads at different time points
108 post-*Mtb* H37Rv-infection demonstrated that, while the load is comparable after two weeks of infection (14
109 dpi), a 3-Log increase in CFU were detected in the lungs of IRG1^{-/-} mice compared to WT mice at 21 dpi
110 (**Figure 1G**). After infection with a similar inoculum of *Mtb* H37Ra or BCG, IRG1^{-/-} mice are not more
111 susceptible for the first 3 weeks. Nevertheless, an increase in the bacterial load in deficient mice is observed
112 during the chronic phase of infection (84 dpi) without any clinical manifestations (**Figure 1G**). In addition,
113 examination of spleen showed *Mtb* H37Rv susceptibility in IRG1^{-/-} mice 21 dpi (**Figure 1H**). A lower level
114 of bacteria was detected in the spleen of BCG and *Mtb* H37Ra infected mice showing the difficulty of these
115 attenuated strains to disseminate in peripheral organs. In the spleen of *Mtb* H37Ra infected mice, bacteria
116 are only detected in IRG1^{-/-} mice 84 dpi (**Figure 1H**).

117 Altogether, these results indicate a major contribution of IRG1 in the antimicrobial host response
118 not only at the mucosal site of infection but also systemically. Our observations in vivo clearly indicate that
119 IRG1^{-/-} mice are highly susceptible to virulent *Mtb* developing a severe phenotype leading to the death of
120 all animals within 3-4 weeks. Infection of IRG1^{-/-} mice with an attenuated mycobacterial strain (*M. bovis*
121 BCG or *Mtb* H37Ra) leads to lower pathogenicity, but these mice still show a higher susceptibility compared
122 to infected WT mice at a late stage post infection. We performed immune cell characterization in WT and
123 IRG1^{-/-} mice during *Mtb* H37Rv infection until 21 dpi by determining the total cell numbers of macrophages,
124 eosinophils, DCs, neutrophils, CD4 T cells, CD8 T cells and B cells in lungs (**Figure S2A**) and spleen
125 (**Figure S2B**). Until 14 dpi, all lung and splenic cell populations were comparable between WT and IRG1^{-/-}
126 mice and did not show remarkable differences (**Figure 2A, Figure S2C**). In contrast, the time period
127 between 14 dpi and 21 dpi led to a dramatic increase in pulmonary macrophages (both alveolar and

128 interstitial ones) as well as neutrophils in the lungs of IRG1^{-/-} mice, while levels of CD4 T cells, CD8 T cells
129 and B cells were significantly decreased compared to WT mice (**Figure 2A**). In the spleen, DCs and
130 neutrophils were significantly increased in IRG1^{-/-} mice at 21 dpi, while CD4 T cells and B cells exhibited a
131 reduction compared to WT cells (**Figure S2C**). These findings demonstrate that macrophages (in the lung),
132 DCs (in the spleen) and neutrophils (in both organs) are the main cell populations that are responsible for
133 the increased progression of *Mtb* infection in IRG1^{-/-} mice. This is underlined by the fact that neutrophils in
134 the lungs of IRG1^{-/-} mice displayed a dramatically higher mycobacterial burden compared to lungs of their
135 WT counterparts, when they were labelled in situ (**Figure 2B**). In line with this, the observed reduction in T
136 cell and B cell levels in both, lung and spleen, of IRG1^{-/-} mice might suggest impaired adaptive immunity in
137 those animals compared to *Mtb*-infected WT mice, which could be beneficial to *Mtb* progression and
138 immunopathology observed in IRG1^{-/-} animals.

139 Immune cell profiling was also characterized during infection of IRG1^{-/-} mice with attenuated *Mtb*
140 H37Ra and BCG. At 21 dpi, the number of recruited neutrophils is much lower in both lungs (**Figure 2C**)
141 and spleen (**Figure 2D**) for mice infected with the attenuated strains compared to mice infected with *Mtb*
142 H37Rv. While infection with the virulent strain induces a decrease in the number of lymphocytes, it was
143 observed that these cells were more prevalent in lungs (**Figure 2C**) and the spleen (**Figure 2D**) of mice
144 infected with the attenuated strains. Together, our observations indicate that the high susceptibility of IRG1^{-/-}
145 mice infected with virulent *Mtb* is associated with high tissue neutrophils count and a failure to recruit
146 adaptive immune response cells.

147 Since the T and B cell response appears to be diminished in infected IRG1^{-/-} mice, we investigated
148 whether these mice had difficulties to establish a protection after vaccination. To do this, C57BL/6 WT and
149 IRG1^{-/-} mice were subcutaneously vaccinated with the *M. bovis* BCG Pasteur vaccine 1173P2. Three
150 months later, the mice were challenged with an intranasal dose of *Mtb* H37Rv similar to previous infection
151 experiments to monitor their degree of protection compared to unvaccinated mice (**Figure 2E**). We first
152 observed that *Mtb* infection was no longer lethal in vaccinated IRG1^{-/-} mice contrary to non-vaccinated ones
153 (**Figure 2F**). These findings imply that IRG1^{-/-} mice are able to develop, like WT mice, a protective immune
154 response after BCG vaccination. To confirm this, we evaluated the pulmonary bacterial load of *Mtb* 21 dpi
155 in WT and IRG1^{-/-} mice, pre-vaccinated or not. The results show that, while unvaccinated IRG1^{-/-} mice are

156 much more susceptible than WT mice, both strains of mice show a similar level of protection in the lungs
157 after vaccination with BCG (**Figure 2G**). Taken together, this means that, while IRG1 plays a very important
158 role in the control of primary infection, it does not impair vaccine protection establishment. Given the critical
159 role of CD4⁺ and CD8⁺ T cells in protection against *Mtb*, it was rather surprising to discover that BCG-
160 vaccinated, IRG1^{-/-} mice were as resistant WT mice to an *Mtb* challenge. This suggests that IRG1 may also
161 affect phagocytes, which are important mediators for the generation of protective innate immunity against
162 TB [33] and led us to further investigate the cell biology of IRG1^{-/-} phagocytes.

163 Given the role of IRG1 as a mitochondrial enzyme of the TCA cycle that is induced upon
164 inflammation and infection, we first studied the metabolic activity of bone marrow-derived macrophages
165 (BMDMs) derived from WT and IRG1^{-/-} mice by microscale oxygraphy using the Seahorse approach. To
166 probe the glycolytic activity of resting and activated BMDMs, glucose, oligomycin A, and 2-deoxyglucose
167 (2-DG) were sequentially injected and the extracellular acidification rate (ECAR) was measured (**Figure**
168 **3A**). While injected glucose is serving to feed glycolysis, oligomycin A is inhibiting ATP synthase in the
169 electron transport chain and changes the ATP/ADP ratio [34]. The addition of 2-DG is inhibiting glycolysis
170 and terminates the experiment and therefore provides a non-glycolytic measurement of ECAR at baseline
171 levels. We observed a high glycolytic reserve capacity in resting IRG1^{-/-} macrophages compared to resting
172 WT cells demonstrated by increased ECAR values over the entire measurement period (**Figure 3A**). Also,
173 upon activation of BMDMs by overnight stimulation with LPS and IFN γ , IRG1^{-/-} cells exhibited elevated
174 ECAR values compared to their WT counterparts. To test mitochondrial respiration of cells as an indicator
175 of oxidative phosphorylation activity, we also performed measurements of the oxygen consumption rate
176 (OCR). Injection of oligomycin A decreases electron flow and leads to a reduction of mitochondrial
177 respiration, which is followed by addition of carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP),
178 a protonophoric uncoupling agent that is collapsing the proton gradient and is disrupting the mitochondrial
179 membrane potential [35]. The terminal injection of rotenone and antimycin A shuts down mitochondrial
180 respiration and allows the calculation of non-mitochondrial OCR. IRG1^{-/-} macrophages did not show
181 differences (or only very minor, negligible ones) in their OCR compared to WT cells at both resting and
182 activated conditions (**Figure 3B**). In addition, we also calculated the mitochondrial spare respiratory
183 capacity (SRC), which is the difference between maximal and basal respiration, that correlates with the bio-

184 energetic adaptability of mitochondria in response to pathophysiological stress conditions [36]. We found
185 that IRG1^{-/-} macrophages have an increased SRC at both resting and activated conditions compared to WT
186 macrophages (**Figure 3C**). Together, these data show that IRG1^{-/-} macrophages are characterized by a
187 more glycolytic metabolism, and that their mitochondria remain highly dynamic to meet extra energy
188 requirements (e.g. in response to acute cellular stress and/or infection by pathogens), as displayed by their
189 increased SRC levels.

190 Next, we analyzed the subcellular distribution of mitochondria in *Mtb*-infected BMDMs by confocal
191 microscopy using a marker against TOM40, an import channel of the mitochondrial outer membrane.
192 Mitochondria in both, WT and IRG1^{-/-} macrophages, were found distributed over the entire cell periphery
193 (**Figure 3D**) with mitochondria localized in close vicinity of intracellular *Mtb* (arrows in **Figure 3D**), as
194 reported previously (summarized in [37]). We noted more bacteria in infected IRG1^{-/-} macrophages
195 compared to WT cells, but found mitochondria surrounding *Mtb*-containing vacuoles in both cell types.
196 These findings suggest that IRG1 deficiency does not directly affect mitochondria morphology and possible
197 interactions between *Mtb* and mitochondria.

198 To further examine the contribution of IRG1 during *Mtb* infection *in vitro*, we infected WT and IRG1^{-/-}
199 BMDMs by the virulent *Mtb* H37Rv strain and investigated the profile of *Irg1* gene expression by
200 quantitative RT-PCR during the course of infection. While *Irg1* was not expressed in resting, non-infected
201 BMDMs, and, as expected, in IRG1^{-/-} macrophages, the stimulation of WT cells, but not of IRG1^{-/-} cells, with
202 100 ng/ml LPS and 20 ng/ml IFN γ for 24 h induced *Irg1* expression considerably (**Figure 4A**), in accordance
203 with previous observations [19]. Infection by *Mtb* H37Rv (at MOI=1) also rapidly induced *Irg1* expression in
204 WT BMDMs and showed increased levels between 2 h and 48 h post-infection (hpi), with almost
205 undetectable levels at 96 hpi, comparable to non-infected cells (**Figure 4A**). Full absence of *Irg1* signals in
206 BMDMs obtained from IRG1^{-/-} mice showed the high specificity of the RT-PCR approach (**Figure 4A**). In
207 accordance with our gene expression data, we detected the IRG1 protein by western blotting in lysates of
208 *Mtb* H37Rv-infected WT BMDMs at 24 hpi, 48 hpi and at lower levels at 72 hpi (**Figure 4B**). In addition to
209 BMDMs, LPS stimulation also induced IRG1 expression in bone marrow-derived dendritic cells (BMDCs),
210 as detected in total cell lysates (TCL) from resting *versus* LPS-stimulated BMDCs (**Figure 4C**).

211 Intracellular pathogens, such as *Mtb*, that enter immune cells by phagocytosis, are located in
212 phagosomes, which further interact with endosomal compartments during phagosome maturation. In a
213 previous study, using a well-established phagocytosis model system of antigen-coupled beads, we
214 identified by quantitative mass spectrometry the specific recruitment of IRG1 to phagosomes of LPS-
215 stimulated BMDCs [38]. We confirmed this observation by western blotting analyzing purified latex bead-
216 containing phagosomes (LBP). We found IRG1 present in LBP lysates of LPS-stimulated BMDCs, while it
217 was absent in phagosomal lysates of resting BMDCs (**Figure 4C**). In contrast, lysosome-associated
218 membrane protein 1 (LAMP-1), a membrane glycoprotein originated from late endosomes and lysosomes,
219 was recruited to LBPs of both, resting and LPS-stimulated BMDCs (**Figure 4C**). In addition, previous work
220 on macrophage infection by *Legionella pneumophila* showed that IRG1 could also be recruited to
221 *Legionella*-containing phagosomes [23]. Therefore, we examined a possible association of IRG1 with *Mtb*-
222 containing vacuoles (MCVs). *Mtb*-infected BMDMs were fixed 24 hpi and labeled for IRG1, F-actin and
223 nuclei for analysis by confocal microscopy (**Figure 4D**). IRG1 was found recruited to MCVs, as several
224 IRG1 signals (green) co-localized with *Mtb* signals (red) (**insets of Figure 4D**). In other parts of the cell,
225 IRG1 remained located outside of those vacuoles and was restricted to other cell organelles, such as
226 mitochondria, as demonstrated previously during pro-inflammatory conditions [38]. We further quantified
227 the recruitment of IRG1 to MCVs by confocal microscopy at 24 hpi and 48 hpi, which was evident in 50%
228 to 80% of all analyzed MCVs of WT cells dependent on the investigated time point and experiment, while
229 no signal was found at MCVs of IRG1^{-/-} macrophages (**Figure 4E**). These findings demonstrated that IRG1
230 is induced upon *Mtb* infection, followed by its recruitment to *Mtb*-containing phagosomes, suggesting a role
231 of IRG1 in the intracellular host defense against mycobacteria.

232 To further elucidate this role in murine phagocytes, we infected BMDMs and BMDCs derived from
233 WT mice or IRG1^{-/-} mice with a GFP-expressing *Mtb* H37Rv strain and followed colonization of host cells
234 and *Mtb* replication up to 96 hpi (**Figure 5A**). Cells were grown in 384-well plates and their nuclei were
235 labeled to enable analysis by an automated confocal microscopy approach using in-house multiparametric
236 imaging that allowed acquisition and examination of hundreds of images generating robust and reproducible
237 data sets (**Figure S3A**) [40]. Algorithms were applied to input images, which resulted in segmentation of
238 the different fluorescent signals allowing nuclei detection, cell and bacteria selection and further

239 downstream analysis to determine infection rate and number of bacteria per cell (**Figure S3A**). First, we
240 observed that the efficacy of *Mtb* uptake by WT and IRG1^{-/-} phagocytes were comparable, as determined
241 by the percentages of *Mtb*-infected BMDMs and BMDCs at 2 hpi (**Figure 5B**). We then compared the *Mtb*
242 intracellular area per infected cell, which directly correlates with the number of *Mtb* per cell, which showed
243 no differences between WT and IRG1^{-/-} BMDMs and BMDCs at 2 hpi (**Figure 5C**). In contrast, at 96 hpi the
244 percentages of *Mtb*-infected BMDMs and BMDCs were largely increased in IRG1^{-/-} BMDMs and BMDCs
245 (**Figure 5B**), showing that IRG1 deficiency favors survival and/or intracellular growth of *Mtb*. This was
246 further supported by the fact that at 96 hpi IRG1-deficient BMDMs and BMDCs also had significantly higher
247 *Mtb* numbers per cell compared to WT phagocytes (**Figure 5C**). These findings indicate that the expression
248 of IRG1, induced by *Mtb* infection, and the presence of IRG1 during the course of infection enable host
249 cells to restrict excessive growth and replication of *Mtb*.

250 Previous observations have shown that *Mtb* persistence/replication relies on the availability of host
251 nutrients that the bacteria exploit to build their replicative niche in phagocytes. During infection, the key
252 carbon source for intracellular *Mtb* consists of host lipids that are mainly stored in LDs and are responsible
253 of the foamy phenotype of macrophages inside tuberculosis granuloma [41]. Therefore, we investigated the
254 impact of IRG1 deficiency on the formation of LDs and their availability in host cells during *Mtb* infection *in*
255 *vitro*. We used a specific dye to label neutral lipids, predominantly located in LDs, in BMDMs and BMDCs
256 at 96 hpi, i.e. the time point where differences in *Mtb* replication rates were very prominent. We again
257 applied automated confocal microscopy and multiparametric image analysis to detect and quantify LDs
258 (**Figure S3B**), which were visualized in both cell types (**Figure 5A**). While non-infected BMDMs and BMDCs
259 exhibited very low percentages of LD-positive cells (**Figure 5D**) or low LD numbers per cell (**Figure 5E**),
260 *Mtb* infection increased the rate of LD-positive cells and LD numbers per cell. The percentage of LD-positive
261 cells was further increased in the IRG1^{-/-} BMDMs and BMDCs compared to WT cells (**Figure 5D**), and those
262 cells showed significantly more LDs per cell (**Figure 5E**). While infected WT BMDMs displayed on average
263 2.7 ± 0.3 LDs per cell, infected IRG1^{-/-} BMDMs contained on average 10.4 ± 2.3 LDs per cell (**Figure 5F**).
264 Strikingly, bystander non-infected cell also had increased lipid droplets numbers (**Figure S4**). These results
265 demonstrate clearly that the presence of IRG1 is concomitant with the reduction of LDs in macrophages
266 and DCs during *Mtb* infection. Finally, we also analyzed LD formation in infected BMDMs on the

267 ultrastructural level by performing electron microscopy (**Figure 5G-H**). Similar to our findings by confocal
268 microscopy, we found significantly more LDs per cell in IRG1^{-/-} BMDMs compared to WT cells (**Figure 5I**).
269 Altogether, our data show a correlation of LD formation upon infection and the impact on *Mtb* replication in
270 phagocytes *in vitro*, which is favored in conditions where IRG1 is absent.

271 **Discussion**

272 In this study, we addressed the role of IRG1 in immunometabolic host responses during
273 mycobacterial infections and were able to demonstrate that expression of IRG1 is essential to dampen
274 immunopathology, both *in vitro* and *in vivo*. Our results on IRG1-deficient mice show that upon infection by
275 a virulent *Mtb* strain (H37Rv), but importantly not by attenuated *Mtb* (H37Ra) and by the vaccinal strain *M.*
276 *bovis* BCG, infected animals display high susceptibility and mortality with exacerbated *Mtb* H37Rv loads in
277 lung and spleen at 3-4 weeks post-infection. Moreover, the immunopathological features of H37Rv-infected
278 IRG1^{-/-} mice (increased inflammation and neutrophil infiltration in lungs and spleens) are similar to those
279 reported previously by the Stallings lab [32]. In that study, the authors investigated the impact of IRG1 on
280 *Mtb* infection using a different virulent *Mtb* strain (Erdman) and a different route of inoculation (aerosol
281 versus intranasal infection like in our study). IRG1 expression is also essential to control other virulent
282 bacterial or viral infections, as it was shown previously for *Legionella pneumophila* [23, 24], *Salmonella*
283 *enterica* [28] as well as for *Brucella melitensis* and *B. abortus* [30, 31]. While IRG1^{-/-} mice were more
284 susceptible to *Brucella* infection and rescued the virulence defect of a *S. enterica* mutant, infection of those
285 mice by *Listeria monocytogenes* and influenza A virus did not result in altered susceptibility of infected
286 IRG1^{-/-} animals [32]. In our study, we provide evidence that IRG1^{-/-} mice are only highly susceptible to
287 virulent *Mtb* but not to attenuated mycobacterial species, such as the vaccinal strain *M. bovis* BCG or the
288 attenuated *Mtb* strain H37Ra. The difference in susceptibility depending on microbes and strain
289 pathogenicity suggests the contribution of microbial effectors in the increased pathogenicity linked to the
290 impairment of IRG1 functions. In the context of *Mtb*, the main difference between the two *Mtb* strains
291 (H37Ra and H37Rv) is linked to the secretion of important effectors of the ESX-1 type VII secretion system
292 (T7SS) through the regulation by the transcriptional regulator PhoP [42]. Future studies would need to

293 clarify the relevance of the ESX-1 T7SS and its virulence effectors on altered IRG1 functions by comparing
294 WT and IRG1-deficient mice.

295 Profiling of the different pulmonary immune cell populations after 21 dpi of *Mtb* H37Rv infection,
296 which is corresponding with the end of the acute phase of infection, revealed a massive infiltration of
297 neutrophils, which was accompanied by increased numbers of alveolar and interstitial macrophages. In TB,
298 neutrophils have deleterious as well as host-beneficial roles, and when they are overloaded with bacilli,
299 their abundance in infected tissues correlates with disease severity [43]. In lungs and spleens of IRG1^{-/-}
300 mice, we also observed reduced amounts of CD4⁺ and CD8⁺ T cells, which has not been reported by Nair
301 and colleagues [32], and highlights a possible impact of IRG1 deficiency on the onset of adaptive immunity.
302 Recent findings support the regulatory role of the *Irg1*/itaconate pathway in adaptive immune responses
303 during airway inflammation [44], which will need further exploration. Given the critical role of CD4⁺ and
304 CD8⁺ T cells in protection against *Mtb* [1], it was rather surprising to discover that BCG-vaccinated IRG1^{-/-}
305 mice were as resistant as WT mice to a challenge with *Mtb* H37Rv and further support the findings of a
306 recent study showing the importance of the itaconate pathway in linking innate immune tolerance and
307 trained immunity [45].

308 On the subcellular level, we could show that, similarly to what is strongly established upon LPS/IFN γ
309 stimulation [9, 10, 21], *Irg1* expression is highly induced during *Mtb* infection, which is a transient process
310 due to the demonstrated negative feedback interaction between IRG1 expression and activity of the E3
311 ligase A20 [46, 47]. Furthermore, mycobacterial infections activate IRF1 nuclear translocation and the
312 expression of IRG1. Importantly, in our study we could not only show that MCVs are in close vicinity of
313 mitochondria, but also that IRG1 is recruited to MCVs, as it has been demonstrated previously for vacuoles
314 containing *Legionella pneumophila* [23] and *Salmonella enterica* [28]. The role of direct IRG1 recruitment
315 to pathogenic vacuoles still remains elusive, but one important molecular player in this interaction appears
316 to be Rab32. This GTPase has been identified in a cell-intrinsic host defense mechanism able to restrict
317 the replication of intravacuolar pathogens [48, 49], which has been shown to require IRG1 interaction to
318 facilitate the delivery of itaconate to *Salmonella*-containing vacuoles [28]. Whether a similar mechanism is
319 engaged during IRG1 recruitment to MCVs awaits further investigation. However, a polymorphism in Rab32
320 has been identified and was associated with increased susceptibility to *Mycobacterium leprae* infection [50],

321 which might also affect other mycobacterial infections. IRG1 expression has been shown to be controlled
322 by IRF1 [51], which recently has been demonstrated during *Mycobacterium avium* infection of human
323 macrophages to induce nuclear translocation of IRF1 to induce IRG1 expression [52]. Though the authors
324 did not detect a direct recruitment of IRG1 to vacuoles containing *M. avium*, they were able to see
325 mitochondria in close vicinity of those MCVs and proposed a directed delivery of itaconate to MCVs as a
326 plausible scenario.

327 Importantly, our *in vitro* experiments in *Mtb*-infected BMDMs and BMDCs could show that the
328 recruitment of IRG1 to MCVs is correlated to decreased mycobacterial replication and lower numbers of
329 LDs, while in IRG1^{-/-} phagocytes increased *Mtb* loads and uncontrolled generation of LDs were evident. A
330 previous study showed that LD formation is resulting from immune activation of macrophages as part of
331 their host defense mechanism against *Mtb* infection and is not only induced by the pathogen itself [53]. The
332 authors showed that this HIF1 α -dependent signaling pathway was required for the majority of LD formation
333 in the lungs of *Mtb*-infected mice. On the other hand, *Mtb* is able to counteract fatty acid oxidation via HIF-
334 1 α activation to stimulate foamy macrophage generation [54], a nutrient-rich reservoir shown to be important
335 for *Mtb* persistence. Previous work also showed that *Mtb*-containing vacuoles are able to migrate towards
336 host LDs, and that oxygenated mycolic acids of *Mtb* are contributing to the foamy phenotype of those
337 macrophages [55]. Our findings suggest that IRG1 induction by the host upon *Mtb* infection restricts LD
338 formation to minimize mycobacterial growth, while increased LD generation in IRG1^{-/-} phagocytes favors
339 *Mtb* replication indicating a dependence of this pathogen on host lipids stored in LDs (**Figure S5**).

340 Changes in available host lipids also have direct consequences on the modulation of adaptive
341 immune responses. For example, LD generation was correlated to efficacy and regulation of cross-
342 presentation pathways [56], which include exogenous antigens derived from *Mtb* infection. Our
343 observations that IRG1 deficiency induced a severe reduction in T and B cell compartments in *Mtb*-infected
344 lungs and spleens, further emphasizes the role of players of adaptive immunity in the progression of *Mtb*
345 immunopathologies. Overall, we could show in our study that immunometabolic host responses during *Mtb*
346 infection are essential to control infection outcome and immunopathology. IRG1 expression and itaconate
347 production are one of the key nodes that determine efficient host immunity in TB suggesting that their

348 modulation might be used in the future development of HDTs to improve immunometabolic host responses
349 to *Mtb* infection.

350 **Material and Methods**

351 **Mice.** C57BL/6NJ wild type mice and C57BL/6NJ-*Acod1^{em1(IMPC)J/J}* (IRG1^{-/-}) mice deficient in *Irg1*
352 expression were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). All mice were maintained
353 and breeding was performed in the animal facility of the Pasteur Institute of Lille, France (agreement B59-
354 350009). All experimental procedures received ethical approval by the French Committee on Animal
355 Experimentation and the Ministry of Education and Research (APAFIS#10232-2017061411305485 v6,
356 approved on 14/09/2018). All experiments were performed in accordance with relevant guidelines and
357 regulations.

358 **Murine bone marrow-derived macrophages (BMDM) and dendritic cells (BMDC).** Murine bone-marrow
359 progenitors were obtained by sampling tibias and femur bones from 7 to 12 week-old C57BL/6NJ wild type
360 and IRG1^{-/-} mice. BMDM were obtained by seeding 10⁷ bone marrow cells in 75 cm² flasks in RPMI 1640
361 Glutamax medium (ThermoFisher Scientific) supplemented with 10% heat-inactivated Fetal Bovine Serum
362 (FBS, ThermoFisher Scientific) and 10% L929 cell supernatant containing Macrophage Colony-Stimulating
363 Factor (M-CSF). After 7 days incubation at 37°C in an atmosphere containing 5% CO₂, the BMDM
364 monolayer was rinsed with D-PBS and cells harvested with Versene (ThermoFisher Scientific). BMDC were
365 differentiated as previously described [40]. Briefly, 2x10⁷ murine bone marrow progenitors were seeded in
366 100 ml RPMI-FBS supplemented with 10% J558-conditioned medium containing Granulocyte-Macrophage
367 Colony-Stimulating Factor (GM-CSF) in 500 cm² square petri dishes (Nunc). Cells were incubated at 37°C
368 in 5% CO₂. Fresh medium was added every 3-4 days. On day 10, the supernatant was discarded and
369 adherent cells were harvested using DPBS containing 2 mM EDTA (Sigma-Aldrich). BMDM and BMDC
370 were resuspended into corresponding culture medium to be used for subsequent assays.

371 **Bacteria.** For *in vivo* studies, *Mycobacterium bovis* BCG (strain 1173P2), *Mtb* H37Ra and *Mtb* H37Rv WT
372 strain were grown in Middlebrook 7H9 medium, as described previously [57] [40]. Recombinant strains of

373 *Mtb* H37Rv expressing an enhanced green fluorescent protein (GFP) or a red fluorescent protein DsRed
374 [40] were cultured in Middlebrook 7H9 medium (Difco) supplemented with 10% oleic acid-albumin-dextrose-
375 catalase (OADC, Difco), 0.2% glycerol (Euromedex), 0.05% Tween 80 (Sigma-Aldrich) and 50 µg/ml
376 hygromycin (ThermoFisher Scientific) or 25 µg/ml kanamycin (Sigma-Aldrich) for H37Rv-GFP or H37Rv-
377 DsRed, respectively. Cultures were maintained for 14 days until the exponential phase was reached. Before
378 cell infection, bacilli were washed with Dulbecco's Phosphate Buffered Saline (DPBS, free from MgCl₂ and
379 CaCl₂, ThermoFisher Scientific), resuspended in 10 mL RPMI-FBS and centrifuged at 1000 RPM for 2 min
380 at room temperature to remove bacterial aggregates. Bacterial titer of the suspension was determined by
381 measuring the optical density (OD_{600 nm}) and GFP or DsRed fluorescence on a Victor Multilabel Counter
382 (Perkin Elmer). The bacterial suspension was diluted at the required titer in RPMI-FBS.

383 **Chemicals, Dyes and Antibodies.** 100 ng/ml of ultrapure LPS from *E. coli* 0111:B4 (Invivogen, France)
384 and 20 ng/ml of recombinant mouse IFN γ (ImmunoTools GmbH, Germany) were used to activate BMDMs.
385 Polyclonal anti-*Mycobacterium tuberculosis* LAM (antiserum, Rabbit), NR-13821, was obtained through BEI
386 Resources, NIAID, NIH, USA. Antibodies against IRG1 (Abcam ab122624) and LAMP-1 (BD Biosciences
387 cat. 553792) were used as primary antibodies. Alexa Fluor 488 and 647 secondary antibodies, Hoechst
388 33342 and LipidTox Deep Red were all obtained from ThermoFisher Scientific (USA). DAPI was purchased
389 from Sigma-Aldrich (USA).

390 **Infection of mice and determination of bacterial burden.** Eight to twelve-week-old C57BL/6NJ WT and
391 IRG1^{-/-} mice (n=16 per group) were inoculated with *Mtb* H37Rv (or PBS for control mice) *via* the intranasal
392 (i.n) route (10⁵ CFU/20 µl) as described [58]. After infection, individual body weight and survival of mice
393 were monitored. At indicated time post infection, mice were euthanized and targeted organs (lungs, spleen,
394 liver and draining bronchial lymph node) were harvested for bacterial burden evaluation by colony forming
395 units (CFU) enumeration. Organs were homogenized for 20 min in a tube containing 2.5 mm diameter glass
396 beads and 1 ml of PBS using the MM 400 mixer mill (Retsch GmbH, Haan, Germany). Ten-fold serial
397 dilutions (from 10⁻² to 10⁻⁹) of each sample were plated onto 7H11 medium agar plate (Difco) supplemented
398 with 10% oleic acid-albumin-dextrose-catalase (OADC, Difco). After a three-week growth period at 37°C,
399 CFUs were determined at the appropriate dilution allowing optimal colonies enumeration.

400 **Lung histopathology.** As described previously [59], mice were euthanized, lungs were perfused and fixed
401 overnight at 4°C with 10 % neutral buffered Formalin solution (Sigma-Aldrich) before being embedded in
402 paraffin. Tissues were sliced with a microtome and 5 µm sections were labelled by hematoxylin phloxine
403 saffron (HPS) stain or Ziehl-Neelsen (acid-fast) stain and were examined by light microscopy for
404 anatomopathology, as described previously [58].

405 **Histology by immunofluorescence.** As described previously [59], lungs were perfused and fixed
406 overnight at 4°C with 10 % neutral buffered Formalin solution (Sigma-Aldrich), washed in PBS, and
407 incubated overnight at RT in a 20 % PBS-sucrose solution. Tissues were then embedded in the Tissue-
408 Tek OCT compound (Sakura), frozen in liquid nitrogen, and cryostat sections (10 µm) were prepared. For
409 staining, tissue sections were rehydrated in PBS and incubated in a PBS solution containing 1% blocking
410 reagent (PBS-BR, Boeringer) for 20 min before incubation overnight at 4°C in PBS-BR containing any of
411 the following mAbs or reagents: DAPI nucleic acid (Molecular Probes), phalloidin Alexa fluor 488 (Molecular
412 Probes), Allophycocyanin-coupled BM8 (anti-F4/80, Abcam), Fluorescein-coupled HL3 (anti-CD11c, BD
413 Biosciences), Fluorescein-coupled 145-2C11 (anti-CD3, BD Biosciences), Phycoerythrin-coupled E50-
414 2440 (anti-Siglec-F, BD Biosciences), Alexa fluor 647-coupled 1A8 (anti-Ly6G, Biolegend),
415 Allophycocyanin-coupled RA3-6B2 (anti-CD45/B220, BD Biosciences). Polyclonal anti-*Mtb* LAM
416 (antiserum, Rabbit), NR-13821, was obtained through BEI Resources, NIAID, NIH, USA. 2 hours at RT
417 incubation with Alexa fluor 568-coupled Donkey anti-Rabbit IgG (ThermoFisher Scientific) was added to
418 reveal anti-*Mtb* LAM staining. Slides were mounted in Fluoro-Gel medium (Electron Microscopy Sciences).
419 Labeled tissue sections were visualized with an Axiovert M200 inverted microscope (Zeiss, Jena, Germany)
420 equipped with a high-resolution mono-chrome camera (AxioCam HR, Zeiss). At least three slides were
421 analyzed per organ from three different animals.

422 **Flow cytometry.** Harvested lungs and spleens were cut into small pieces and incubated for 1 hour at 37 °C
423 with a mix of DNase I (100 µg/ml, Sigma-Aldrich) and collagenase D (400 U/ml, Roche). Lung cells were
424 washed and filtered before being incubated with saturating doses of purified 2.4G2 (anti-mouse Fc receptor,
425 ATCC) in 200 µl PBS, 0.2% BSA, 0.02% NaN₃ (FACS buffer) for 20 min at 4 °C. Various fluorescent
426 monoclonal antibody combinations in FACS buffer were used to stain cells. Acquisitions were done on a

427 FACS Canto II flow cytometer (Becton Dickinson) with the following mAbs: Fluorescein (FITC)-coupled 145-
428 2C11 (anti-CD3, BD Biosciences), FITC-coupled HL3 (anti-CD11c, ThermoFisher Scientific),
429 Phycoerythrin (PE)-coupled M1/70 (anti-CD11b, BD Biosciences), PE-coupled 53-6.7 (anti-CD8a, BD
430 Biosciences), Allophycocyanin (APC)-coupled BM8 (anti-F4/80, BD Biosciences), APC-coupled RM4-5
431 (anti-CD4, Biolegend), Brilliant violet 421 (BV421)-coupled E50-2440 (anti-SiglecF, BD Biosciences),
432 BV421-coupled M5 (anti-MHCII, BD Biosciences), PE/cyanine(Cy)7-coupled RA3-6B2 (anti-CD45/B220,
433 BD Biosciences) and PE/Cy7-coupled 1A8 (anti-Ly6G, Biolegend). Fixable viability dye Aqua
434 (ThermoFisher Scientific) was used to gate viable cells.

| Cell type | Phenotype |
|--------------------------|--|
| Neutrophils | CD11b ⁺ Ly6G ⁺ |
| Dendritic cells | CD11b ⁺ CD11c ⁺ F4/80 ⁻ |
| Alveolar macrophages | F4/80 ⁺ SiglecF ⁺ CD11c ⁺ |
| Interstitial macrophages | F4/80 ⁺ SiglecF ⁻ CD11c ^{int} |
| Eosinophils | F4/80 ⁺ SiglecF ⁺ CD11c ⁻ |
| CD4 T cells | CD3 ⁺ CD4 ⁺ |
| CD8 T cells | CD3 ⁺ CD8 ⁺ |
| B cells | B220 ⁺ MHCII ⁺ |

435 **Quantitative RT-PCR.** BMDMs were grown in 6-well plates and RNA was isolated using the RNeasy Mini
436 kit (Qiagen) following the manufacturer's instructions. RNA concentration was determined using the GE
437 SimpliNano device (GE Healthcare). Remaining DNA in samples was digested using the amplification grade
438 DNase I kit (Sigma-Aldrich) for 6 min at RT. The reaction was stopped by heat inactivation for 10 min at
439 70°C. cDNA synthesis was achieved by reverse transcription using the SuperScript VILO kit (ThermoFisher
440 Scientific) following the manufacturer's instructions. qPCR was performed using the LightCycler 480 SYBR
441 Green I reagent (Roche) with 20 ng cDNA per sample and the indicated primer pairs (**Supplemental Table**
442 **S1**). qPCR reactions were measured by the QuantStudio 12K Flex system (Applied Biosystems) using the
443 following cycles: 2 min 50°C, 10 min 95°C followed by 40 cycles of 15 s at 95°C, 30 s at 60°C and 30 s at
444 72°C.

445 **Infection for intracellular mycobacterial replication and lipid droplet (LD) formation assays.** 2×10^4
446 BMDM or 4×10^4 BMDC were seeded per well in 384-well plates (μ Clear, Greiner Bio-One). After 12 hours

447 incubation at 37°C with 5% CO₂, LPS (100 ng/mL) and IFN-gamma (50 ng/mL) were added as positive
448 control. After overnight incubation, cells were infected for 2 h with H37Rv-GFP at a MOI of 1. Cells were
449 washed with RPMI-FBS and treated with amikacin (50 µg/mL) for 1 h in order to remove extracellular *Mtb*.
450 Then, cells were washed twice with RPMI-FBS and incubated at 37°C with 5% CO₂.

451 For intracellular mycobacterial replication assay, 10% formalin solution (Sigma-Aldrich) containing
452 10 µg/mL Hoechst 33342 (ThermoFisher Scientific) was replaced to each well at 2 h and 96 h post-infection.
453 Plates were incubated at RT for 30 min, allowing staining and cell fixation. Cells were stored in DPBS
454 supplemented with 1% FBS, until image acquisition.

455 For LD formation assay, cells were washed and fixed at 96 h post-infection, as previously described
456 [40]. Cells were washed twice with DBPS and intracellular LDs were stained with 25 µL per well of 2000-
457 fold diluted HCS LipidTOX deep Red neutral lipid probe (ThermoFisher Scientific) in PBS for 30 min at
458 room temperature.

459 **Image Acquisition.** Image acquisitions were performed on an automated confocal microscope (Opera
460 QEHS, PerkinElmer) using a 20x and 60x water objectives for intracellular mycobacterial replication and
461 LD formation assays, respectively. The microscope was equipped with 405 nm, 488 nm, 561 nm and 640
462 nm excitation lasers. The emitted fluorescence was captured using three cameras associated with a set of
463 filters covering a detection wavelength ranging from 450 nm to 690 nm. Hoechst 33342-stained nuclei were
464 detected using the 405 nm laser with a 450/50-nm emission filter. Green or red signals, corresponding to
465 H37Rv-GFP and H37Rv-DsRed, were recorded using 488 nm or 561 nm lasers with 540/75- or 600/40-nm
466 emission filters, respectively. LipidTOX signal was detected using 630-nm excitation and 690-nm emission
467 wavelengths.

468 **Image-based analysis.** For mycobacteria replication and LD generation quantification, images from the
469 automated confocal microscope were analyzed using multi-parameter scripts developed using Columbus
470 system (version 2.3.1; PerkinElmer) as described previously [40] (**Supplemental Tables 2 and 3**).

471 *Cell detection and M. tuberculosis intracellular replication*

472 Segmentation algorithms were applied to input images to detect nuclei labeled by Hoechst 33342 (cyan)
473 and the GFP signal of *Mtb* H37Rv (green) to determine infection and replication rates. Briefly, the host cell

474 segmentation was performed using two different Hoechst signal intensities—a strong intensity
475 corresponding to the nucleus and a weak intensity in cytoplasm—with the algorithm “Find Nuclei” and “Find
476 Cytoplasm”, as described previously [60]. GFP or DsRed signal intensities in a cell were used for the
477 intracellular bacterial segmentation with the algorithm “Find Spots”. The identified intracellular bacteria were
478 quantified as intracellular *Mtb* area with number of pixels. Subsequently, population of infected cells was
479 determined, and the increase of intracellular *Mtb* area, corresponding to intracellular mycobacterial
480 replication, was calculated.

481 *Cell detection and quantification of LD formation*

482 LDs labeled by LipidTox DeepRed (red), nuclei labeled by Hoechst 33342 (blue) and the GFP signal of *Mtb*
483 H37Rv (green) were detected using segmentation algorithms applied to input image. Briefly, the host cell
484 segmentation using Hoechst signal and LipidTox intensities was performed to detect nuclei and cell
485 borders, respectively. *Mtb* and LDs were determined by applying masks, which were adapted to GFP and
486 LipidTox dye signal intensities, respectively. Further filtering and refinement using the algorithm “Find
487 Micronuclei” and based on size-to-signal intensity and area of LD candidates allowed specific selection of
488 LDs, which were separated from out-of-focus and background signal intensities. The identified intracellular
489 bacteria were quantified as intracellular *Mtb* area with number of pixels. Subsequently, population of
490 infected (*Mtb*) and non-infected (NI) cells were determined, and the percentage of LD-positive cells and the
491 average of LD number per cell were calculated.

492 **Immunofluorescence.** BMDMs were grown overnight on poly-L-lysine-coated glass coverslips the day
493 before the infection. Cells were infected with *Mtb* H37Rv-DsRed at an MOI = 1 for 24 h. Subsequently, cells
494 were washed three times with PBS and fixed in PBS + 4% paraformaldehyde + 4% sucrose, pH 7.4, for 20
495 min at RT followed by quenching in PBS + 50 mM NH₄Cl for 10 min. Coverslips were labeled for IRG1
496 (Abcam, UK), DNA using DAPI (Sigma-Aldrich, USA) and F-actin using Alexa Fluor 680 phalloidin
497 (ThermoFisher Scientific). After extensive washing, the coverslips were post-fixed in 4% paraformaldehyde
498 for 16 h and then mounted with ProLong Gold antifade reagent (ThermoFisher Scientific). Images were
499 acquired using a confocal microscope (Zeiss LSM880) equipped with a 63x objective (NA 1.4) and Zen
500 imaging software (Zeiss, Germany).

501 **Processing for conventional electronic microscopy.** Infected BMDMs were fixed 4 days post-infection
502 at room temperature for 1 h with 2.5% glutaraldehyde in Na-cacodylate buffer 0.1 M (pH 7.2) containing
503 0.1 M sucrose, 5 mM CaCl₂, and 5 mM MgCl₂, washed with complete cacodylate buffer and post-fixed for
504 1 h at room temperature with 1% osmium tetroxide in the same buffer devoid of sucrose. Cells were washed
505 with the same buffer, scraped off the dishes and concentrated in 2% agar in Na-cacodylate buffer.
506 Subsequently, samples were washed twice in Na-cacodylate buffer and dehydrated in a graded series of
507 acetone solutions and gradually incorporated in Spurr resin. Ultrathin sections (80 nm) were cut with an
508 ultracryomicrotome (EM UC7, Leica) and were stained with 1% uranyl acetate in ultrapure water and then
509 with Reynolds reagent. Samples were analyzed with a Tecnai G2 20 TWIN (200 kV) transmission electron
510 microscope (FEI) and digital images were acquired with a digital camera (Eagle, FEI) for further
511 quantification. For image analysis, precautions were taken to avoid analysis of serial cuts, and 100 WT
512 BMDMs and 64 IRG1^{-/-} BMDMs were examined randomly by TEM to determine the number of bacteria and
513 number of lipid granules per cell.

514 **Western Blotting.** Latex bead-containing phagosomes (LBPs) were isolated as described previously [22].
515 LBP pellets were lysed in 2% (v/v) Triton X-100, 50 mM Tris, pH 8.0, 10 mM dithiothreitol, 2x protease
516 inhibitor mixture (Roche, France) for 30 min on ice. Phagosomal lysates and total cell lysates (TCL) were
517 mixed with 5x Laemmli sample buffer and boiled for 5 min at 95 °C. Samples were loaded on 4-15%
518 Criterion TGX protein gels (Bio-Rad) and run in 25 mM Tris, 192 mM glycine, 0.1% (m/vol) SDS, pH 8.3, at
519 100 V. Proteins were transferred onto 0.2 µm PVDF membranes by a Trans-Blot Turbo device (Bio-Rad)
520 at 2.5 A for 7 min. Equal loading of samples was controlled by Ponceau S staining. After transfer,
521 membranes were blocked in 5% dry milk and incubated with primary antibodies and peroxidase-conjugated
522 secondary antibodies. Bound antibodies were revealed using Chemiluminescence Blotting Substrate from
523 Roche according to the manufacturers' suggestions.

524 **Microscale oxygraphy.** Real-time extracellular acidification rate (ECAR) and oxygen consumption rate
525 (OCR) were measured using the Seahorse XFe24 flux analyzer (Seahorse Bioscience, Agilent) as
526 described previously [61]. Briefly, BMDMs were seeded at a density of 1.6x10⁶ cells/ml the day before the
527 measurement and incubated at 37°C and 5% CO₂. BMDMs were treated or not with 100 ng/ml of ultrapure

528 LPS and 20 ng/ml of recombinant mouse IFN γ for 18 h. On the day of the measurement, culture medium
529 was removed and cells were washed once with assay medium consisting of DMEM (Sigma-Aldrich), pH
530 buffered at 7.35, supplemented with 10 mM glucose and 2 mM glutamine and were incubated at 37 °C for
531 30 min. After baseline measurements, ECAR was analyzed after injections of D-glucose (10 mM),
532 oligomycin A (1 μ M), an ATP synthase inhibitor, and 2-deoxyglucose (10 mM), a competitive inhibitor of
533 glucose. Similarly, after baseline measurements, OCR was analyzed after subsequent injection of
534 oligomycin A (1 μ M), two injections of carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP,
535 0.27 μ M and then 0.34 μ M), a protonophore, and injection of a rotenone/antimycin A mix (1 μ M), inhibitors
536 of complex III and I. Mitochondrial spare reserve capacity (SRC) was calculated by subtracting basal
537 respiration from maximal respiratory capacity as described previously [36].

538 **Statistics.** All analyses and histograms were performed using GraphPad Prism 7 software. Significance of
539 obtained results was tested using Mantel-Cox test (survival of *Mtb*-infected mice) and by Mann-Whitney
540 test (Plating of CFU of different organs, immune cell profiling). Differences in the mean between two groups
541 were analyzed using Student's t-test (*in vitro* replication and LD experiments). Indicated symbols of *, **
542 and *** denote $p < 0.05$, $p < 0.01$ and $p < 0.001$, respectively.

543 **Author contributions**

544 A.M., P.B., and E.H. conceived the study and wrote the manuscript. A.M., I.B., N.D., I.P., J-P.S-A., A-M.P.,
545 O-R.S., S.J., C.R., A.P., S.M., W.L., J.K., and S.C. performed and analyzed experiments. J-P.S-A., C.R.,
546 J.K., E.M., R.B., and S.C. provided reagents. S.M. and L.M. provided expertise and feedback on the study.
547 P.B. and E.H. secured funding.

548 **Acknowledgments**

549 We gratefully acknowledge Alexandre Vandeputte, Gerald Larrouy-Maumus, Ruxandra Gref, Tom
550 Bourguignon, Alain Baulard, Cyril Gaudin, Muriel Pichavant, Isabelle Ricard, and Martin Cohen-Gonsaud
551 for technical assistance and helpful discussions. We thank Nicolas Vandenamee and Robin Prath for
552 expert BSL-3 animal facility assistance. We acknowledge the PICT-IBiSA, Elisabeth Werkmeister, Hélène
553 Bauderlique and Frank Lafont from BiCEL for providing access to microscopy and flow cytometry
554 equipment. Financial support for this work was provided by the European Community (CycloNHit n°
555 608407, ERC-STG INTRACELLTB n° 260901), the Agence Nationale de la Recherche (ANR-10-EQPX-
556 04-01, ANR-14-CE08-0017, ANR-16-CE35-0009, ANR-18-JAM2-0002, ANR-20-CE44-0019), the EMBO
557 Young Investigator Program, the Feder (12001407 (D-AL) Equipex Imaginex BioMed), the I-SITE ULNE
558 Foundation (ERC Generator Grant) and the Fondation pour la Recherche Medicale (SPF20170938709).
559 The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
560 the manuscript.

561 **References**


- 562 [1] Kinsella RL, Zhu DX, Harrison GA, Mayer Bridwell AE, Prusa J, Chavez SM, et al. Perspectives and
563 Advances in the Understanding of Tuberculosis. *Annu Rev Pathol.* 2021;16: 377-408.
- 564 [2] World Health Organization (WHO). Global tuberculosis report 2021.
565 <https://www.who.int/teams/global-tuberculosis-programme/tb-reports>
- 566 [3] Darrah PA, Zeppa JJ, Maiello P, Hackney JA, Wadsworth MH 2nd, Hughes TK, et al. Prevention of
567 tuberculosis in macaques after intravenous BCG immunization. *Nature.* 2020;577: 95-102.
- 568 [4] Machelart A, Song OR, Hoffmann E, Brodin P. Host-directed therapies offer novel opportunities for
569 the fight against tuberculosis. *Drug Discov Today.* 2017;22: 1250-1257.
- 570 [5] Escoll P, Buchrieser C. Metabolic reprogramming: an innate cellular defence mechanism against
571 intracellular bacteria? *Curr Opin Immunol.* 2019;60: 117-123.
- 572 [6] Rosenberg G, Riquelme S, Prince A, Avraham R. Immunometabolic crosstalk during bacterial
573 infection. *Nat Microbiol.* 2022;7: 497-507.
- 574 [7] Russell DG, Huang L, VanderVen BC. Immunometabolism at the interface between macrophages
575 and pathogens. *Nat Rev Immunol.* 2019;19: 291-304.
- 576 [8] O'Neill LA, Pearce EJ. Immunometabolism governs dendritic cell and macrophage function. *J Exp
577 Med.* 2016;213: 15-23.
- 578 [9] Strelko CL, Lu W, Dufort FJ, Seyfried TN, Chiles TC, Rabinowitz JD, et al. Itaconic acid is a
579 mammalian metabolite induced during macrophage activation. *J Am Chem Soc.* 2011;133: 16386-
580 16389.
- 581 [10] Seim GL, Britt EC, John SV, Yeo FJ, Johnson AR, Eisenstein RS, et al. Two-stage metabolic
582 remodelling in macrophages in response to lipopolysaccharide and interferon- γ stimulation. *Nat
583 Metab.* 2019;1: 731-742.
- 584 [11] Shin JH, Yang JY, Jeon BY, Yoon YJ, Cho SN, Kang YH, et al. (1)H NMR-based metabolomic
585 profiling in mice infected with *Mycobacterium tuberculosis*. *J Proteome Res.* 2011;10: 2238-2247.
- 586 [12] O'Neill LAJ, Artyomov MN. Itaconate: the poster child of metabolic reprogramming in macrophage
587 function. *Nat Rev Immunol.* 2019;19: 273-281.
- 588 [13] Peace CG, O'Neill LA. The role of itaconate in host defense and inflammation. *J Clin Invest.*
589 2022;132: e148548.
- 590 [14] Michelucci A, Cordes T, Ghelfi J, Pailot A, Reiling N, Goldmann O, et al. Immune-responsive gene 1
591 protein links metabolism to immunity by catalyzing itaconic acid production. *Proc Natl Acad Sci U S
592 A.* 2013;110: 7820-7825.
- 593 [15] McKinney JD, Höner zu Bentrup K, Muñoz-Eliás EJ, Miczak A, Chen B, Chan WT, et al. Persistence
594 of *Mycobacterium tuberculosis* in macrophages and mice requires the glyoxylate shunt enzyme
595 isocitrate lyase. *Nature.* 2000;406: 735-738.
- 596 [16] Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE, Loginicheva E, et al.
597 Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and
598 Regulation of Inflammation. *Cell Metab.* 2016;24: 158-166.

- 599 [17] Swain A, Bambouskova M, Kim H, Andhey PS, Duncan D, Auclair K, et al. Comparative evaluation
600 of itaconate and its derivatives reveals divergent inflammasome and type I interferon regulation in
601 macrophages. *Nat Metab.* 2020;2: 594-602.
- 602 [18] Hooftman A, Angiari S, Hester S, Corcoran SE, Runtsch MC, Ling C, et al. The Immunomodulatory
603 Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation. *Cell Metab.* 2020;32:
604 468-478.e7.
- 605 [19] Bambouskova M, Potuckova L, Paulenda T, Kerndl M, Mogilenko DA, Lizotte K, et al. Itaconate
606 confers tolerance to late NLRP3 inflammasome activation. *Cell Rep.* 2021;34: 108756.
- 607 [20] Mills EL, Ryan DG, Prag HA, Dikovskaya D, Menon D, Zaslona Z, et al. Itaconate is an anti-
608 inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. *Nature.* 2018;556: 113-117.
- 609 [21] Bambouskova M, Gorvel L, Lampropoulou V, Sergushichev A, Loginicheva E, Johnson K, et al.
610 Electrophilic properties of itaconate and derivatives regulate the I κ Bzeta-ATF3 inflammatory
611 axis. *Nature.* 2018;556: 501-504.
- 612 [22] Runtsch MC, Angiari S, Hooftman A, Wadhwa R, Zhang Y, Zheng Y, et al. Itaconate and itaconate
613 derivatives target JAK1 to suppress alternative activation of macrophages. *Cell Metab.* 2022;34: 487-
614 501.e8.
- 615 [23] Naujoks J, Tabeling C, Dill BD, Hoffmann C, Brown AS, Kunze M, et al. IFNs Modify the Proteome
616 of Legionella-Containing Vacuoles and Restrict Infection Via IRG1-Derived Itaconic Acid. *PLoS*
617 *Pathog.* 2016;12: e1005408.
- 618 [24] Price JV, Russo D, Ji DX, Chavez RA, DiPeso L, Lee AY, et al. IRG1 and Inducible Nitric Oxide
619 Synthase Act Redundantly with Other Interferon-Gamma-Induced Factors To Restrict Intracellular
620 Replication of Legionella pneumophila. *mBio.* 2019;10: e02629-19.
- 621 [25] Riquelme SA, Lozano C, Moustafa AM, Liimatta K, Tomlinson KL, Britto C, et al. CFTR-PTEN-
622 dependent mitochondrial metabolic dysfunction promotes Pseudomonas aeruginosa airway
623 infection.
- 624 [26] Daniels BP, Kofman SB, Smith JR, Norris GT, Snyder AG, Kolb JP, et al. The Nucleotide Sensor
625 ZBP1 and Kinase RIPK3 Induce the Enzyme IRG1 to Promote an Antiviral Metabolic State in
626 Neurons. *Immunity.* 2019;50: 64-76.e4.
- 627 [27] Jessop F, Buntyn R, Schwarz B, Wehrly T, Scott D, Bosio CM. Interferon Gamma Reprograms Host
628 Mitochondrial Metabolism through Inhibition of Complex II To Control Intracellular Bacterial
629 Replication. *Infect Immun.* 2020;88: e00744-19.
- 630 [28] Chen M, Sun H, Boot M, Shao L, Chang SJ, Wang W, et al. Itaconate is an effector of a Rab GTPase
631 cell-autonomous host defense pathway against Salmonella. *Science.* 2020;369: 450-455.
- 632 [29] Tomlinson KL, Lung TWF, Dach F, Annavajhala MK, Gabryszewski SJ, Groves RA, et al.
633 Staphylococcus aureus induces an itaconate-dominated immunometabolic response that drives
634 biofilm formation. *Nat Commun.* 2021;12: 1399.
- 635 [30] Demars A, Vitali A, Comein A, Carlier E, Azouz A, Goriely S, et al. Aconitate decarboxylase 1
636 participates in the control of pulmonary Brucella infection in mice. *PLoS Pathog.* 2021;17: e1009887.
- 637 [31] Lacey CA, Ponzilacqua-Silva B, Chambers CA, Dadelahi AS, Skyberg JA. MyD88-Dependent
638 Glucose Restriction and Itaconate Production Control Brucella Infection. *Infect Immun.* 2021;89:
639 e0015621.

- 640 [32] Nair S, Huynh JP, Lampropoulou V, Loginicheva E, Esaulova E, Gounder AP, et al. Irg1 expression
641 in myeloid cells prevents immunopathology during *M. tuberculosis* infection. *J Exp Med.* 2018;215:
642 1035-1045.
- 643 [33] Kaufmann E, Sanz J, Dunn JL, Khan N, Mendonça LE, Pacis A, et al. BCG Educates Hematopoietic
644 Stem Cells to Generate Protective Innate Immunity against Tuberculosis. *Cell.* 2018;172: 176-190.
- 645 [34] TeSlaa T, Teitell MA. Techniques to monitor glycolysis. *Methods Enzymol.* 2014;542: 91-114.
- 646 [35] Divakaruni AS, Paradyse A, Ferrick DA, Murphy AN, Jastroch M. Analysis and interpretation of
647 microplate-based oxygen consumption and pH data. *Methods Enzymol.* 2014;547: 309-354.
- 648 [36] Marchetti P, Fovez Q, Germain N, Khamari R, Kluza J. Mitochondrial spare respiratory capacity:
649 Mechanisms, regulation, and significance in non-transformed and cancer cells. *FASEB J.* 2020;34:
650 13106-13124.
- 651 [37] Mohareer K, Medikonda J, Vadankula GR, Banerjee S. Mycobacterial Control of Host Mitochondria:
652 Bioenergetic and Metabolic Changes Shaping Cell Fate and Infection Outcome. *Front Cell Infect*
653 *Microbiol.* 2020;10: 457.
- 654 [38] Pauwels AM, Härtlova A, Peltier J, Driege Y, Baudelet G, Brodin P, et al. Spatiotemporal Changes
655 of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation. *Mol Cell Proteomics.*
656 2019;18: 909-922.
- 657 [39] Tallam A, Perumal TM, Antony PM, Jäger C, Fritz JV, Vallar L, et al. Gene Regulatory Network
658 Inference of Immunoresponsive Gene 1 (IRG1) Identifies Interferon Regulatory Factor 1 (IRF1) as
659 Its Transcriptional Regulator in Mammalian Macrophages. *PloS One.* 2016;11: e0149050.
- 660 [40] Deboosere N, Belhaouane I, Machelart A, Hoffmann E, Vandeputte A, Brodin P. High-Content
661 Analysis Monitoring Intracellular Trafficking and Replication of *Mycobacterium tuberculosis* Inside
662 Host Cells. *Methods Mol Biol.* 2021;2314: 649-702.
- 663 [41] Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy macrophages and the progression of
664 the human tuberculosis granuloma. *Nat Immunol.* 2009;10: 943-948.
- 665 [42] Frigui W, Bottai D, Majlessi L, Monot M, Josselin E, Brodin P, et al. Control of *M. tuberculosis* ESAT-
666 6 secretion and specific T cell recognition by PhoP. *PLoS Pathog.* 2008;4: e33.
- 667 [43] Borkute RR, Woelke S, Pei G, Dorhoi A. Neutrophils in Tuberculosis: Cell Biology, Cellular
668 Networking and Multitasking in Host Defense. *Int J Mol Sci.* 2021;22: 4801.
- 669 [44] Jaiswal AK, Yadav J, Makhija S, Mazumder S, Mitra AK, Suryawanshi A, et al. Irg1/itaconate
670 metabolic pathway is a crucial determinant of dendritic cells immune-priming function and contributes
671 to resolute allergen-induced airway inflammation. *Mucosal Immunol.* 2022;15: 301-313.
- 672 [45] Domínguez-Andrés J, Novakovic B, Li Y, Scicluna BP, Gresnigt MS, Arts RJW, et al. The Itaconate
673 Pathway Is a Central Regulatory Node Linking Innate Immune Tolerance and Trained Immunity. *Cell*
674 *Metab.* 2019;29: 211-220.e5.
- 675 [46] Van Quickenberghe E, Martens A, Goeminne LJE, Clement L, van Loo G, Gevaert K. Identification
676 of Immune-Responsive Gene 1 (IRG1) as a Target of A20. *J Proteome Res.* 2018;17: 2182-2191.
- 677 [47] Catrysse L, Maes B, Mehrotra P, Martens A, Hoste E, Martens L, et al. A20 deficiency in myeloid
678 cells protects mice from diet-induced obesity and insulin resistance due to increased fatty acid
679 metabolism. *Cell Rep.* 2021;36: 109748.


- 680 [48] Spanò S, Galán JE. A Rab32-dependent pathway contributes to *Salmonella typhi* host restriction.
681 *Science*. 2012;338: 960-963.
- 682 [49] Spanò S, Gao X, Hannemann S, Lara-Tejero M, Galán JE. A Bacterial Pathogen Targets a Host
683 Rab-Family GTPase Defense Pathway with a GAP. *Cell Host Microbe*. 2016;19: 216-226.
- 684 [50] Zhang F, Liu H, Chen S, Low H, Sun L, Cui Y, et al. Identification of two new loci at IL23R and RAB32
685 that influence susceptibility to leprosy. *Nat Genet*. 2011;43: 1247-1251.
- 686 [51] Tallam A, Perumal TM, Antony PM, Jäger C, Fritz JV, Vallar L, et al. Gene Regulatory Network
687 Inference of Immunoresponsive Gene 1 (IRG1) Identifies Interferon Regulatory Factor 1 (IRF1) as
688 Its Transcriptional Regulator in Mammalian Macrophages. *PLoS One*. 2016;11: e0149050.
- 689 [52] Gidon A, Louet C, Røst LM, Bruheim P, Flo TH. The Tumor Necrosis Factor Alpha and Interleukin 6
690 Auto-paracrine Signaling Loop Controls *Mycobacterium avium* Infection via Induction of IRF1/IRG1
691 in Human Primary Macrophages. *mBio*. 2021;12: e0212121.
- 692 [53] Knight M, Braverman J, Asfaha K, Gronert K, Stanley S. Lipid droplet formation in *Mycobacterium*
693 *tuberculosis* infected macrophages requires IFN- γ /HIF-1 α signaling and supports host defense.
694 *PLoS Pathog*. 2018;14: e1006874.
- 695 [54] Genoula M, Marín Franco JL, Maio M, Dolotowicz B, Ferreyra M, Milillo MA, et al. Fatty acid oxidation
696 of alternatively activated macrophages prevents foam cell formation, but *Mycobacterium tuberculosis*
697 counteracts this process via HIF-1 α activation. *PLoS Pathog*. 2020;16: e1008929.
- 698 [55] Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, et al. Foamy macrophages
699 from tuberculous patients' granulomas constitute a nutrient-rich reservoir for *M. tuberculosis*
700 persistence. *PLoS Pathog*. 2008;4: e1000204.
- 701 [56] Bougnères L, Helft J, Tiwari S, Vargas P, Chang BH, Chan L, et al. A role for lipid bodies in the cross-
702 presentation of phagocytosed antigens by MHC class I in dendritic cells. *Immunity*. 2009;31: 232-
703 244.
- 704 [57] Raze D, Verwaerde C, Deloison G, Werkmeister E, Coupin B, Loyens M, et al. Heparin-Binding
705 Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in
706 *Mycobacteria*. *Front Microbiol*. 2018;9: 2258.
- 707 [58] Costa-Gouveia J, Pancani E, Jouny S, Machelart A, Delorme V, Salzano G, et al. Combination
708 therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded
709 nanoparticles. *Sci Rep*. 2017;7: 5390.
- 710 [59] Machelart A, Salzano G, Li X, Demars A, Debie AS, Menendez-Miranda M, et al. Intrinsic
711 Antibacterial Activity of Nanoparticles Made of β -Cyclodextrins Potentiates Their Effect as Drug
712 Nanocarriers against Tuberculosis. *ACS Nano*. 2019;13: 3992-4007.
- 713 [60] Song OR, Deboosere N, Delorme V, Queval CJ, Deloison G, Werkmeister E, et al. Phenotypic assays
714 for *Mycobacterium tuberculosis* infection. *Cytometry A*. 2017;91: 983-994.
- 715 [61] Kluza J, Peugnet V, Daunou B, Laine W, Kervoaze G, Rémy G, et al. A New Strategy to Preserve
716 and Assess Oxygen Consumption in Murine Tissues. *Int J Mol Sci*. 2021;23: 109.

717 **Figures**



718

719 **Figure 1. IRG1-deficient mice are highly susceptible to infection by virulent *Mtb*.** (A) Workflow of the experimental
 720 setup during intranasal (i.n.) infection of WT mice and IRG1^{-/-} mice with the indicated mycobacterial strains and the
 721 different read-out time points at days post-infection (dpi). (B) Changes in body weight of WT mice and IRG1^{-/-} mice and
 722 (C) their survival rates after intranasal administration of *Mtb* H37Rv (red), *Mtb* H37Ra (blue) and *M. bovis* BCG (black).
 723 (D) Photographs of representative examples of the left lung lobe of WT mice and IRG1^{-/-} mice infected by *Mtb* H37Rv
 724 at 21 dpi. (E) Immunopathology of mouse lungs infected by *Mtb* H37Rv at 21 dpi, as determined by hematoxylin
 725 phloxine saffron staining of histological sections. (F) The mycobacterial load in lungs of WT mice and IRG1^{-/-} mice
 726 infected by *Mtb* H37Rv at 21 dpi was determined by acid-fast stain (Ziehl-Neelsen staining) of representative
 727 histological sections. Insets display labeled mycobacteria in purple (arrows). (G) Determination of the mycobacterial
 728 burden of the left lung lobe of WT and IRG1^{-/-} mice by counting colony-forming units (CFU) of administered intranasal
 729 inoculums (i.n.) and the indicated mycobacterial strains at different days post-infection. (H) CFU determination of
 730 spleens of mice infected by the indicated mycobacterial strains. Shown are mean ± SD. Statistical differences were
 731 determined by survival Log-rank (Mantel-Cox) test (C) and by non-parametric Mann-Whitney test (G, H). ns: non-
 732 significant, * P value < 0.05, ** P value < 0.01, *** P value < 0.001.




733

734 **Figure 2. Adaptive immune responses help to overcome susceptibility of IRG1^{-/-} mice to virulent *Mtb* infection.**


735 (A) Profiling of lung immune cells of WT mice and IRG1^{-/-} mice during the course of *Mtb* H37Rv infection. Histograms
 736 depict changes in cell numbers of the indicated immune cell populations, as determined by flow cytometry using specific
 737 cell surface markers. All cell numbers were normalized to the total cell number analyzed in each sample and were
 738 extrapolated to the whole organ. Shown are mean ± SEM of cells obtained from three individual mice per group. (B)
 739 Representative images of lung tissue cryosections obtained from *Mtb* H37Rv-infected WT mice and IRG1^{-/-} mice at 21
 740 dpi and acquired by confocal microscopy. Mycobacteria (red) were labeled with a specific lipoarabinomannan (LAM)

741 antibody, while neutrophils (white) were labeled with an antibody against Ly6G. Bar: 50 μ m. **(C-D)** Differences in
742 neutrophil numbers and adaptive immune cell populations of IRG1^{-/-} mice infected by *Mtb* H37Rv (red), *Mtb* H37Ra
743 (blue) and *M. bovis* BCG (black). Shown are percent levels of the indicated cell types in **(C)** pulmonary cell populations
744 and **(D)** splenic cell populations at 21 dpi. **(E)** Workflow of the experimental setup of vaccination of WT mice and IRG1^{-/-}
745 mice by subcutaneous (s.c.) injection of *M. bovis* BCG followed by intranasal (i.n.) challenge with *Mtb* H37Rv. Control
746 mice received s.c. injections of PBS. **(F)** Survival rate of BCG-vaccinated mice (green) and PBS-injected control mice
747 (black) after intranasal challenge with *Mtb* H37Rv at a similar dose shown in Figure 1C. **(G)** Determination of
748 mycobacterial loads in left lung lobes of BCG-vaccinated (vacc.) and control WT and IRG1^{-/-} mice by CFU counting 21
749 days after challenge with *Mtb* H37Rv. Shown are mean \pm SD. Statistical differences were determined by non-parametric
750 Mann-Whitney test (A, G), by ANOVA and Bonferroni post-hoc correction for multiple comparisons (C, D) and survival
751 Log-rank (Mantel-Cox) test (F). ns: non-significant, * P value < 0.05, ** P value < 0.01, *** P value < 0.001.




752

753 **Figure 3. IRG1 $^{-/-}$ macrophages are characterized by a more glycolytic metabolism, and *Mtb* are found in close**
 754 **vicinity of mitochondria of both, WT and IRG1 $^{-/-}$ cells. (A-C)** Glycolysis and mitochondrial respiration were measured
 755 by Seahorse analysis determining (A) extracellular acidification rate (ECAR) and (B) oxygen consumption rate (OCR)
 756 of bone marrow-derived macrophages (BMDM), respectively. Cells were analyzed in resting conditions and after
 757 stimulation with 100 ng/ml LPS and 20 ng/ml IFN γ for 18 h. Injection of substrates and different inhibitors occurred at
 758 the indicated time points (more details in the methods section). (C) Bio-energetic plasticity of mitochondria of BMDMs
 759 in response to pathophysiological stress conditions was calculated by their spare respiratory capacity (SRC). 2-DG: 2-
 760 deoxy-D-glucose, FCCP: carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazine, AA: antimycin A. (D) BMDMs
 761 obtained from WT mice (left) and IRG1 $^{-/-}$ mice (right) were infected by *Mtb* H37Rv-DsRed (red), fixed at 48 hpi and
 762 analyzed by confocal microscopy. Mitochondria were labeled with an antibody against TOM40 (green), a marker of the
 763 mitochondrial outer membrane, and nuclei were stained with DAPI (blue). Arrows indicate *Mtb* in close vicinity to
 764 mitochondria. Bar: 10 μ m. Statistical differences between matching WT and IRG1 $^{-/-}$ samples were determined by two-
 765 way ANOVA with a 95% confidence interval followed by Bonferroni's post-test (A-C). * P value < 0.05, *** P value <
 766 0.001.



767

768 **Figure 4. *Irg1* expression is induced by *Mtb* infection and IRG1 is recruited to *Mtb*-containing vacuoles. (A)**
 769 BMDMs of WT mice and IRG1^{-/-} mice were either treated with 100 ng/ml LPS and 20 ng/ml IFN γ or infected with *Mtb*
 770 H37Rv for the indicated time points. Non-infected (NI) cells served as control. Transcription of *Irg1* was assessed by
 771 quantitative RT-PCR and normalized to the expression of glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*).
 772 Shown are mean \pm SEM obtained from BMDMs of three different mice. **(B)** Expression of IRG1 protein in total cell
 773 lysates (TCL) of WT and IRG1^{-/-} BMDMs infected with *Mtb* H37Rv for the indicated time points as detected by western
 774 blotting. Expression of Actin is shown as loading control. One experiment representative of three independent ones is
 775 shown. **(C)** Detection of IRG1 and LAMP-1 by western blotting in TCL and purified fractions of latex bead-containing
 776 phagosomes (LBP) of bone marrow-derived dendritic cells (BMDC) obtained from WT mice. BMDCs were analyzed at
 777 resting state (left) or 16 h after the addition of 100 ng/ml LPS (right). **(D)** Confocal image of the subcellular localization
 778 of *Mtb* H37Rv-DsRed (red) and IRG1 (green) in WT BMDM at 24 h post-infection (hpi). The nucleus was labeled with
 779 DAPI (blue), while F-actin was visualized by Phalloidin staining (gray). Insets (right panel) depict different focal planes
 780 of the same area showing co-localization of IRG1 to *Mtb* phagosomes. **(E)** Recruitment of IRG1 to *Mtb*-containing
 781 vacuoles (MCV) in WT BMDMs and IRG1^{-/-} BMDMs was assessed by confocal microscopy and by manual analysis of
 782 focal planes of entire cells. Shown are mean \pm SEM of 3 (24 hpi) and 4 (48 hpi) independent experiments analyzing at
 783 least 30 infected cells per condition.



784

785 **Figure 5. IRG1 deficiency leads to increased *Mtb* replication and increased amounts of lipid droplets (LDs) in**
 786 **phagocytes. (A)** WT BMDMs (upper panel) and IRG1^{-/-} BMDMs (lower panel) were left non-infected (NI) or infected
 787 with *Mtb* H37Rv-GFP (green) for the indicated time points. Alternatively, cells were also treated with 100 ng/ml LPS
 788 and 20 ng/ml IFN γ for 24 h. All cells were fixed and labeled with DAPI and LipidTOX DeepRed to stain nuclei (blue)
 789 and LDs (red), respectively. Shown are representative images acquired by automated confocal microscopy and image
 790 analysis. Bar: 10 μ m. **(B-F)** BMDMs and BMDCs were grown in 384-well plates, infected with *Mtb* H37Rv-GFP (green)
 791 and analyzed by automated confocal microscopy. **(B)** Histograms displaying the percentage of infected BMDMs (left


792 panel) and BMDCs (right panel) at 2 hpi and 96 hpi. **(C)** Histograms showing the bacterial area per infected BMDM (left
793 panel) and infected BMDC (right panel) at both time points, which directly correlates with the number of *Mtb* per infected
794 cell. **(D)** Histograms depicting the percentage of LD-positive NI and *Mtb*-infected BMDMs (left panel) and BMDCs (right
795 panel) at 96 hpi, as determined by automated confocal microscopy. **(E)** Histograms showing the average LD number
796 per cell for both cell types at 96 hpi. Shown are mean \pm SEM of at least 6 analyzed wells per condition ($n > 400$ cells)
797 of one representative out of three independent experiments. **(F)** LD numbers of BMDMs at 96 hpi ($n=100$) were also
798 counted manually in a blinded fashion to verify accuracy of the automated image analysis pipeline. **(G-I)** Ultrastructural
799 analysis of LD formation in *Mtb*-infected BMDMs derived from WT mice **(G)** and IRG1^{-/-} mice **(H)** at 96 dpi by electron
800 microscopy. Bar: 2 μ m. **(I)** Numbers of lipid droplets (indicated as LD in the inset) were quantified in WT cells ($n=100$)
801 and IRG1^{-/-} cells ($n=64$). Statistical differences were determined by Student's t-test (ns: non-significant, * P value <
802 0.05, ** P value < 0.01, *** P value < 0.001).

803 **Supplemental figures**



804

805 **Figure S1. Mouse lungs infected by different mycobacterial strains at 84 dpi.** WT mice (A) and of IRG1^{-/-} mice (B)
806 were infected intranasally as indicated in Fig. 1A with the indicated mycobacterial strains and their lungs analyzed for
807 pathological differences at 84 dpi.



808

809

810

811

812

813

814

815

816

817


818

819

820


Figure S2. Flow cytometry analysis of pulmonary and splenic subpopulations of infected mice. Flow cytometry gating strategies for pulmonary and splenic cell populations of interest. Cells were first identified using forward scatter (FSC) and side scatter (SSC) gates to exclude residual red blood cells and cellular fragments. Among these, alive cells were selected using a fixable viability dye (Zombie Aqua). Whole organ cell tissues were stained to identify different immune cell types. **(A)** In lungs, neutrophils were selected after gating CD11b⁺ and Ly6G⁺ cells (CD11b⁺ Ly6G⁺), while classical dendritic cells were identified using positive selection of CD11b and CD11c markers on cells negative for F4/80 (F4/80-CD11b⁺ CD11c⁺). On positive F4/80 cells, SiglecF and CD11c markers were used to discriminate eosinophils (F4/80⁺ SiglecF⁺ CD11c⁻), alveolar macrophages (MØ) (F4/80⁺ SiglecF⁺ CD11c⁺) and interstitial MØ (F4/80⁺ SiglecF⁻ CD11c^{int}). B cells were identified using MHCII and CD45/B220 markers (MHCII⁺ B220⁺). CD3, CD4 and CD8 markers were used to select CD4⁺ T cells (CD3⁺ CD8⁻ CD4⁺) and CD8⁺ T cells (CD3⁺ CD8⁺ CD4⁻), respectively. **(B)** In spleens, similar gating strategies were used to select neutrophils, classical dendritic cells, B lymphocytes, CD4 T cells and CD8 T cells. Macrophages were discriminated by the selection of F4/80⁺ cells among

821 the CD11b+ Ly6G- cell population (CD11b+ Ly6G- F4/80+). **(C)** Profiling of splenic immune cells of WT mice and IRG1-
822 ^{-/-} mice during the course of *Mtb* H37Rv infection. Histograms depict changes in cell numbers of the indicated immune
823 cell populations, as determined by flow cytometry using specific cell surface markers. All cell numbers were normalized
824 to the total cell number analyzed in each sample and were extrapolated to the whole organ. Shown are mean ± SEM
825 of cells obtained from three individual mice per group. Statistical differences were determined by non-parametric Mann-
826 Whitney test (* P value < 0.05, ** P value < 0.01).



827

828 **Figure S3. Workflows of the applied automated, multiparametric image analysis pipeline using Columbus**
829 **software. (A)** Workflow to assess the intracellular replication of *Mtb* in BMDMs and BMDCs. Segmentation algorithms
830 were applied to input images of WT cells (upper panel) and IRG1^{-/-} cells (lower panel) to detect nuclei and cell borders
831 (labeled by Hoechst 33342) and to identify *Mtb* H37Rv (expressing GFP) to determine infection and replication rates.
832 In the right panel, infected cells are depicted in green, while non-infected cells are shown in red. Cells only partially
833 shown in the microscopy field (depicted in gray) were excluded from the analysis. Bar: 50 μ m. **(B)** Workflow to quantify
834 the generation of lipid droplets (LDs). BMDMs and BMDCs were labeled with LipidTox DeepRed to visualize LDs (red),
835 nuclei were labeled by Hoechst 33342 (blue) and the GFP signal of *Mtb* H37Rv (green). Segmentation algorithms were
836 used to detect cell borders and *Mtb* followed by an LD mask adapted to LipidTox dye signal intensities. Further filtering
837 and refinement based on size-to-signal intensity allowed specific selection of LDs (green circles in the right images),
838 which were separated from out-of-focus and background signal intensities (red circles in the right image panel). Insets
839 show magnifications of LDs of example cells. Bar: 20 μ m. Further details of the applied scripts are indicated in
840 Supplemental tables 2 and 3.



841

842

843

844


845

846

847

848

Figure S4. IRG1 deficiency leads to increased amounts of lipid droplets (LDs) in infected as well as non-infected bystander phagocytes. (A) Histograms depicting the percentage of LD-positive, *Mtb*-infected BMDCs (left panel) and non-infected bystander BMDCs (right panel) at 96 hpi, as determined by automated confocal microscopy. (B) Histograms showing the average LD number per cell for infected and non-infected bystander BMDCs at 96 hpi. Shown are mean \pm SEM of at least 6 analyzed wells per condition ($n > 400$ cells) of one representative out of three independent experiments. Statistical differences were determined by Student's t-test (ns: non-significant, * P value < 0.05, *** P value < 0.001).



849

850 **Figure S5. Induced expression of IRG1 during *Mtb* infection restricts formation of lipid droplets and**
851 **intracellular pathogen growth.** Infection of alveolar macrophages by *Mtb*, which leads to recruitment of IRG1 to *Mtb*-
852 containing vacuoles (inset) in WT conditions (left panel), restricts generation of lipid droplets, an important nutrient
853 reservoir of *Mtb* in host cells. Limited availability of host lipids confines intracellular replication of the pathogen and
854 permits induction of adaptive immune responses. Absence of IRG1 during *Mtb* infection (right panel) leads to
855 uncontrolled formation of lipid droplets and exacerbated pathogen growth in host cells. Increased inflammation in the
856 lung and infiltration of neutrophils further allows *Mtb* dissemination and reduces numbers of recruited B and T
857 lymphocytes, which possibly attenuate adaptive immunity.

858 **Supplemental tables**

859 **Table S1.** Sequences of the RT-PCR primers used in this study.

| Gene | forward primer sequence | reverse primer sequence |
|--------------|--------------------------------|--------------------------------|
| <i>Irg1</i> | GGCACAGAAGTGTTCCATAAAGT | GAGGCAGGGCTTCCGATAG |
| <i>Gapdh</i> | TGGCCTTCCGTCTCCCTAC | GAGTTGCTGTTGAAGTCGCA |

860

861 **Table S2.** Applied in-house multi-parametric script used in Columbus (PerkinElmer) to determine *Mtb*
 862 replication.

| Input Image | Stack Processing: Individual Planes Flat field Correction: None | Method | Output |
|--|--|---|---|
| Calculate Image | | Method : By Formula Formula : $\text{iif}(A>200,A,0)$ Channel A : Exp1Cam1 Negative Values : Set to Zero Undefined Values : Set to Local Average | Output Image : DAPImask |
| Find Nuclei | Channel : DAPImask ROI : None | Method : B Common Threshold : <u>0.8</u> Area : > 30 μm^2 Split Factor : 7 Individual Threshold : 0.4 Contrast : > 0.1 | Output Population : Nuclei |
| Find Cytoplasm | Channel : Exp1Cam1 Nuclei : Nuclei | Method : A Individual Threshold : <u>0.3</u> | |
| Select Population | Population : Nuclei | Method : Common Filters Remove Border Objects Region : Cell | Output Population : Cells selected |
| Calculate Image | | Method : By Formula Formula : $\text{iif}(A>200, A, 0)$ Channel A : Exp2Cam2 Negative Values : Set to Zero Undefined Values : Set to Local Average | Output Image : Mtb Mask |
| Find Spots | Channel : Mtb Mask ROI : Cells selected | Method : A Relative Spot Intensity : > 0.03 Splitting Coefficient : <u>0.54</u> Calculate Spot Properties | Output Population : Intracellular Mtb |
| Calculate Morphology Properties | Population : Intracellular Mtb Region : Spot | Method : Standard Area | Output Properties : Intracellular Mtb |
| Calculate Properties | Population : Cells selected | Method : By Related Population Related Population : Intracellular Mtb Number of Intracellular Mtb Intracellular Myb Area [px^2] | Output Properties : per Cell |
| Select Population | Population : Cells selected | Method : Filter by Property Number of Intracellular Mtb- per Cell : > 0 | Output Population : Infected cells |
| Define Results | Method: List of Outputs Number of Objects Population : Intracellular Mtb Intracellular Mtb Area [px^2] : Sum Population : Infected Cells Intracellular Mtb Area [px^2]- Sum per Cell : Mean Method : Formula Output Formula : $a/b*100$ Population Type : Objects Variable A : Infected Cells - Number of Objects Variable B : Cells Selected - Number of Objects Output Name : % Infected cells | | |

863

864 **Table S3.** Applied in-house multi-parametric script used in Columbus (PerkinElmer) to determine lipid
865 droplet generation.

| Input Image | Stack Processing: Individual Planes Flat field Correction: None | Method | Output |
|--|---|---|-----------------------------------|
| Calculate Image | | Method : By Formula Formula : iif(A>150, A, 0) Channel A : Exp1Cam1 Negative Values : Set to Zero Undefined Values : Set to Local Average | Output Image : DAPI mask |
| Calculate Image | | Method : By Formula Formula : iif(A>200,A,0) Channel A : Exp2Cam2 Negative Values : Set to Zero Undefined Values : Set to Local Average | Output Image : Mtb Mask |
| Calculate Image | | Method : By Formula Formula : iif(A>350,A,0) Channel A : Exp2Cam3 Negative Values : Set to Zero Undefined Values : Set to Local Average | Output Image : LD Mask |
| Find Nuclei | Channel : DAPI mask ROI : None | Method : B Common Threshold : <u>0.4</u> Area : > 20 μm^2 Split Factor : 7 Individual Threshold : <u>0.4</u> Contrast : > 0.1 | Output Population : Nuclei |
| Find Cytoplasm | Channel : Exp2Cam3 Nuclei : Nuclei | Method : B Common Threshold : <u>0.2</u> Individual Threshold : <u>0.2</u> | |
| Find Spots | Channel : Mtb Mask ROI : Nuclei | Method : B Detection Sensitivity : 0.5 Splitting Coefficient : 0.5 Calculate Spot Properties | Output Population : Mtb |
| Calculate Properties | Population : Nuclei | Method : By Related Population Related Population : Mtb Number of Mtb Spot Area [px ²] | Output Properties : per Cell |
| Find Micronuclei | Channel : Exp2Cam3 Population : Nuclei Cell Region : Cell | Method : A Micronucleus to Cytoplasm Intensity : > 0.15 Calculate Micronuclei Properties Unit for Properties : px | Output Population : LD candidates |
| Calculate Morphology Properties | Population : LD candidates Region : Micronucleus | Method : Standard Area Roundness | Output Population : LD candidate |
| Select Population | Population : LD | Method : Filter by Property Spot to Region Intensity : >= <u>1</u> Spot Contrast : > <u>0.1</u> Boolean Operations : F1 and F2 | Output Population : LD candidates |

| | | | |
|---------------------------------------|--|--|--|
| Select Population | Population : LD candidates | Method : Filter by Property LD candidates Area [px ²] : <= 45 | Output Population : : LD selected |
| Calculate Intensity Properties | Channel : Exp2Cam3 Population : LD Selected Region : Micronucleus | Method : Standard Mean Maximum | Output Population : Intensity LD Selected Exp2Cam3 |
| Calculate Properties | Population : Nuclei | Method : By Related Population Related Population : LD Selected Number of LD Selected LD candidates Area [px ²] Intensity LDselected Exp2Cam3 Mean Intensity LDselected Exp2Cam3 Maximum | Output Properties : per Cell |
| Select Population | Population : Nuclei | Method : Filter by Property Number of Mtb- per Cell : >= 1 | Output Population : IFC |
| Select Population | Population : Nuclei | Method : Filter by Property Number of Mtb- per Cell : == 0 | Output Population : Non-IFC |
| Select Population | Population : IFC | Method : Filter by Property Number of LD Selected- per Cell : >= 1 | Output Population : LDPosIFC |
| Select Population | Population : Non-IFC | Method : Filter by Property Number of LD Selected- per Cell : >= 1 | Output Population : LDPosNon-IFC |
| Define Results | <p>Method: List of Outputs Population : Mtb Spot Area [px²] : Sum Population : LD Selected Intensity LDselected Exp2Cam3 Mean : Mean Intensity LDselected Exp2Cam3 Maximum : Mean Population : LDPosIFC Number of LD Selected- per Cell : Sum LD candidates Area [px²]- Sum per Cell : Sum Intensity LDselected Exp2Cam3 Mean- Mean per Cell : Mean Intensity LDselected Exp2Cam3 Maximum- Mean per Cell : Mean Population : LDPosNon-IFC Number of LD Selected- per Cell : Sum LD candidates Area [px²]- Sum per Cell : Sum Intensity LDselected Exp2Cam3 Mean- Mean per Cell : Mean Intensity LDselected Exp2Cam3 Maximum- Mean per Cell : Mean</p> <p>Method : Formula Output Formula : a/b*100 Population Type : Objects Variable A : IFC - Number of Objects Variable B : Nuclei - Number of Objects Output Name : % <u>Infected cell</u></p> <p>Method : Formula Output Formula : a/b*100 Population Type : Objects Variable A : LDPosIFC - Number of Objects Variable B : IFC - Number of Objects Output Name : % <u>LDPosIFC</u></p> <p>Method : Formula Output Formula : a/b*100 Population Type : Objects Variable A : LDPosNon-IFC - Number of Objects</p> | | |

Variable B : Non-IFC - Number of Objects
Output Name : % LDPosNon-IFC

Method : Formula Output
Formula : a/b
Population Type : Objects
Variable A : IFC - Number of LD Selected- per Cell Sum
Variable B : IFC - Number of Objects
Output Name : LD number/IFC

Method : Formula Output
Formula : a/b
Population Type : Objects
Variable A : NonIFC - Number of LD Selected- per Cell Sum
Variable B : NonIFC - Number of Objects
Output Name : LD number/NonIFC

Method : Formula Output
Formula : a/b
Population Type : Objects
Variable A : IFC - Number of LD Selected- per Cell Sum
Variable B : LDposIFC - Number of Objects
Output Name : LD number/LDposIFC

Method : Formula Output
Formula : a/b
Population Type : Objects
Variable A : NonIFC - Number of LD Selected- per Cell Sum
Variable B : LDposNonIFC - Number of Objects
Output Name : LD number/LDposNonIFC
